

The Top 3 Biotech Stocks to Own

The meteoric rise in biotech stocks isn't over just yet.

In fact, "The outlook for 2021 for biotech is still very positive because the fundamentals are intact, innovation is continuing" and access to capital hasn't been an issue, said Wendy Lam, a portfolio manager at Franklin Templeton., as quoted by Bloomberg. Industry success in quickly developing shots to fight the virus, "shine a light on how important the sector is for society."

Plus, there's also incredible new innovation in genetics and technology. In fact, over the next several years, genetic testing and gene editing will help to identify and potentially cure diseases. And three, big pharmaceutical companies are buying hot biotech companies to keep their pipelines full to avoid revenue shortfalls.

In short, biotech will continue to be one of the hottest opportunities to consider.

Here are three of the top ones we believe could run to higher highs in the New Year.

Biotech Stock No. 1 – Anavex Life Sciences Corp. (AVXL)

Shares of AVXL already exploded from a low of \$10.50 to \$25, but it could see further upside.

For one, the company just reported progress in a Phase 2 trial of its Parkinson's disease drug, Anavex 2-73. "Treatment with Anavex2-73 not only slows the progression of motor and non-motor symptoms in moderately advanced patients with Parkinson's," said the company. "Anavex2-73 also resulted in clinically meaningful improvements as measured by the global composite score of Parkinson's disease symptom severity, and other metrics."

Two, the company is seeing positive results in Phase 2 trials of a treatment of Rett Syndrome, a central nervous system disease caused by a mutation of the MECP2 gene. "Walter Kaufmann, Anavex's chief medical officer, said the clinical improvements following a biomarker change — the increase in sigma-1 receptors — are promising for early intervention in Rett Syndrome," as reported by Investors' Business Daily.

Biotech Stock No. 2 – TG Therapeutics (TGTX)

TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing two therapies targeting hematological malignancies and autoimmune diseases.

The company recently posted positive top line results from two Phase 3 studies for its Ublituximab treatment of multiple sclerosis patients. In fact, it just reported positive topline results from two global, active-controlled, Phase 3 studies, called ULTIMATE I & II, evaluating ublituximab, the Company's investigational novel, glycoengineered anti-CD20 monoclonal antibody, compared to teriflunomide in patients with relapsing forms of multiple sclerosis (RMS). Both studies met their primary endpoint.

Lawrence Steinman, MD, Zimmermann Professor of Neurology, and Pediatrics at Stanford University and Global Study Chair for the ULTIMATE I & II studies said, "B-cell targeted therapy with anti-CD20 monoclonal antibodies has dramatically shifted the treatment paradigm for patients with MS and has shown to be very effective in reducing relapses in patients."

Biotech Stock No. 3 – SpringWorks Therapeutics (SWTX)

SpringWorks Therapeutics, Inc., a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in

Phase III clinical trial for the treatment of desmoid tumors, which are aggressive fibromatosis or desmoid-type fibromatosis that are rare and often debilitating and disfiguring soft-tissue tumors.

Over the last year, SWTX exploded from \$30 to \$84.

However, there could be further upside ahead. For one, it just signed clinical collaborations with Janssen, Pfizer, and Precision Biosciences to evaluate nirogacestat in combination with BCMA-directed therapies.

Two, it and Precision BioSciences just announced that the first patient has been dosed in the combination arm of Precision's Phase 1/2a trial evaluating PBCAR269A. In the study, Precision's investigational allogeneic BCMA-targeted CAR T cell therapy will be combined with nirogacestat, SpringWorks' investigational gamma secretase inhibitor (GSI), in patients with relapsed/refractory (R/R) multiple myeloma, according to a company press release.